期刊文献+

丙型肝炎病毒感染至临床诊断肝癌的病程经过 被引量:6

Course analysis: from HCV infection to hepatocellular carcinoma
下载PDF
导出
摘要 目的 探讨丙型肝炎病毒 (HCV)感染发展为肝硬化、肝细胞癌的平均临床病程。方法 收集我院收治的73例感染HCV的肝癌患者病例资料 ,对其从HCV感染发展为慢性肝炎、肝硬化和肝癌病程经过进行统计学分析。结果 输血至临床诊断为肝癌的平均时间为 ( 2 0 .83± 11.63 )年 ,临床诊断慢性丙型肝炎至肝硬化平均时间为 ( 11.91± 11.0 6)年 ;慢性肝炎发展为肝癌的平均时间为 ( 12 .2 1± 11.90 )年 ,肝硬化至临床诊断肝癌 ( 3 2例 )平均病程为 ( 3 .0 3± 2 .84)年。结论 HCV感染发展为肝细胞癌的病程进展缓慢 ,有输血史的患者较无输血者平均病程短。 Objective To study the course from HCV infection to the development of hepatocellular. carcinoma and related factors.Methods 73 hepatocellular carcinoma patients with HCV infection were included. The course from HCV infection to liver cirrhosis and hepatocellular carcinoma,the influence of associated HBV infection and alcoholic liver disease to the course were analyzed. Results The mean interval between the date of blood transfusion and hepatocellular carcinoma was 20.83±11.63 years. The mean interval between diagnosis of chronic hepatitis C and liver cirrhosis was 11.91±11.06 years, and that of hepatocellular carcinoma was 12.21±11.90 years. The mean interval between diagnosis of liver cirrhosis and hepatocellular carcinoma was 3.03±2.84 years. Conclusion The progress from HCV infection through cirrhosis and hepatocellular carcinoma was slow. The progress was faster in patients with blood transfusion history than those without.
出处 《肝脏》 2004年第1期8-10,共3页 Chinese Hepatology
关键词 丙型肝炎病毒感染 诊断 肝癌 病程 肝硬化 Hepatitis C virus Hepatocarcinoma Progress
  • 相关文献

参考文献12

  • 1WHO Consultation. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatitis,1999, 6:35-47.
  • 2Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis.N Engl J Med, 1997, 336 : 347-356.
  • 3NIH: National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology, 1997, 26:s2-10.
  • 4Beasley RP, Hwang LY, Lin CC, et al. Hepatocelluar carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan.Lancet, 1981, 2:1129-1133.
  • 5Farinati F, Fagiooli S. Anti-HCV positive hepatocellular carcinoma in cirrhosis. Prevalence-risk factors and clinleal features. J Hepatol,1992, 14:183-187.
  • 6Ramesh R, Munshi A, Panda SK. Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatoeellular carcinoma patients in India. J Gastroenterol Hepatol, 1992, 7:393-396.
  • 7WHO Consultation. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatitis,1999, 6: 35-47.
  • 8Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis.N EnglJ Med, 1997, 336:347-356.
  • 9NIH: National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology, 1997, 26:s2-10.
  • 10Beasley RP, Hwang LY, Lin CC, et al. Hepatocelluar carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan.Lancet, 1981, 2:1129-1133.

同被引文献48

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2谢立,吴晓东.丙型肝炎病毒检测方法的研究进展及其临床意义[J].世界华人消化杂志,2005,13(7):884-886. 被引量:56
  • 3宋花玲,贺佳,虞慧婷,李玲.应用ROC曲线下面积对两相关诊断试验进行评价和比较[J].第二军医大学学报,2006,27(5):562-563. 被引量:73
  • 4AKAHOSHI H, TAURA N, ICHIKAWA T, et al.Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma[J]. Oncol Rep. 2010,23:1317-- 1323.
  • 5SHEPARD C W, FINELLI L, ALTER M J. Global epidemiology of hepatitis C virus infection [J]. Lancet Infect Dis, 2005,5 : 558-- 567.
  • 6中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华肝脏病杂志,2004;12:194-198.
  • 7WHO第63届世界卫生大会.病毒性肝炎秘书处的报告.2010:1-30.
  • 8Plancoulaine S, Mohamed MK, Arafa N, et al. Dissection of familial correlations in hepatitis C virus (HCV) seroprevalence suggests intrafamilial viral transmission and genetic predisposition to infection. Gut, 2008,57 : 1268-1274.
  • 9Omata M,Kanda T, Yu ML,et al. and management algorithms for Hepatol Int,2012,6:409-435.
  • 10APASL consensus statements hepatitis C virus infection. European Association for the Study of the Liver.EASL clinical practice guidelines:management of hepatitis C virus infection .J Hepatol, 2011,55:245-264.

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部